Diabetes Drug Actos (Pioglitazone) and Bladder Cancer Risks
Actos-The FDA has approved updated drug labels for Actos, usually prescribed to treat Type 2 diabetes. The new label states that the use of the drug for more than one year may be associated with an increased risk of bladder cancer.
The US FDA aproved Actos in 1999. It is manufactured by Takeda Chemical Industries. It includes the active ingredient pioglitazone hydrochloride, is used for treatment of type 2 and type 1 diabetes; type 1 diabetes mellitus; diabetes mellitus inadequate control; and high blood pressure.
Following are Actos drugs:
- ActoPlus Met (active ingredient: metformin hydrochloride; pioglitazone hydrochloride)
- Pioglitazone hydrochloride and metformin hydrochloride (active ingredient: metformin hydrochloride; pioglitazone hydrochloride)
- Actos (active ingredient: pioglitazone hydrochloride)
- ActoPlus Met XR (active ingredient: metformin hydrochloride; pioglitazone hydrochloride)
- Pioglitazone (active ingredient: pioglitazone hydrochloride)
- DueTact (active ingredient: glimepiride; pioglitazone hydrochloride)